Harmony Biosciences (NASDAQ:HRMY – Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Tuesday, October 29th. Analysts expect Harmony Biosciences to post earnings of $0.66 per share for the quarter. Harmony Biosciences has set its FY 2024 guidance at EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.24. Harmony Biosciences had a net margin of 17.53% and a return on equity of 22.97%. The company had revenue of $172.80 million for the quarter, compared to analyst estimates of $172.53 million. During the same period in the prior year, the business earned $0.56 earnings per share. Harmony Biosciences’s quarterly revenue was up 28.8% on a year-over-year basis. On average, analysts expect Harmony Biosciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Harmony Biosciences Price Performance
Shares of HRMY stock opened at $34.50 on Friday. Harmony Biosciences has a 1 year low of $19.03 and a 1 year high of $40.60. The firm’s 50 day moving average is $36.40 and its 200-day moving average is $32.96. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of 17.69, a PEG ratio of 0.69 and a beta of 0.73. The company has a current ratio of 3.13, a quick ratio of 3.09 and a debt-to-equity ratio of 0.32.
Analysts Set New Price Targets
View Our Latest Analysis on Harmony Biosciences
Harmony Biosciences Company Profile
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Read More
- Five stocks we like better than Harmony Biosciences
- What is the Dow Jones Industrial Average (DJIA)?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Financial Services Stocks Investing
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Manufacturing Stocks Investing
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.